期刊文献+

美托洛尔治疗慢性充血性心力衰竭30例疗效观察 被引量:1

下载PDF
导出
摘要 目的探讨美托洛尔治疗慢性充血性心力衰竭的临床效果。方法所选的60例慢性心力衰竭患者均为我院2010年1月至2013年1月收治的住院病例,上述患者随机分为观察组和对照组。观察组和对照组患者均给予强心苷类药物强心、给予利尿剂利尿、同时给予血管紧张素转换酶抑制剂类药物,同时纠正水电解质紊乱和维持酸碱平衡。在此基础上,观察组患者同时给予美托洛尔。上述患者均连续治疗12周。观察患者心功能及疗效。结果观察组和对照组治疗后心率、收缩压、左室射血分数分别与本组治疗前比较,差异有统计学意义(P<0.05)观察组治疗后心率、收缩压、左室射血分数分别与对照组治疗后比较,差异有统计学意义(P<0.05);观察组总有效率(96.7%)和对照组总有效率(73.3%)比较,差异有统计学意义(P<0.05)。结论美托洛尔在慢性充血性心力衰竭的治疗中疗效显著,有助于改善患者心功能,值得借鉴。
作者 陈允
出处 《中国医药指南》 2013年第25期135-136,共2页 Guide of China Medicine
  • 相关文献

参考文献6

二级参考文献44

  • 1王效增,邹德莉,邱毓骦.美托洛尔治疗老年冠心病慢性心力衰竭52例疗效观察[J].解放军保健医学杂志,2005,7(4):208-210. 被引量:5
  • 2刘鹏,张新勇,刘宇,关怀敏,解金红.曲美他嗪和美托洛尔治疗合并糖尿病稳定型心绞痛的疗效观察[J].中国医师杂志,2007,9(4):554-555. 被引量:3
  • 3柳韶真,董淼伟.美托洛尔治疗老年慢性心力衰竭临床研究[J].解放军保健医学杂志,2007,9(1):32-33. 被引量:8
  • 4[1]Macdonald PS,Hill J,Krum H.COLA Ⅱ Investigators.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
  • 5[2]Dobre D,van Veldhuisen DJ.SENIORS Investigators.Tolerability and dose-related effects of nebivolol in elderly patients with heart failure:data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial[J].Am Heart J,2007,154 (1):109-115.
  • 6[3]Willenheimer R,van Veldhuisen DJ,CIBIS Ⅲ Investigators.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ.Circulation,2005,112(16):2426-2435.
  • 7[4]Chuen M J,MacFadyen RJ.Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure[J].Am J Cardiol,2006,98(10):1416-1417.
  • 8[5]Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297 (12):1332-1343.
  • 9[6]Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331.
  • 10[7]Cleland JG,Coletta AP,Clark AL.Clinical trials update from the American College of Cardiology 2007:ALPHA,EVEREST,FUSION Ⅱ,VALIDD,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP for the evaluation of dyspnoea and THIS-diet[J].Eur J Heart Fail,2007,9(6-7):740-745.

共引文献114

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部